Leads Biolabs lists on HKEX, raises $189 million in IPO

Published 25/07/2025, 02:14
© Reuters.

Nanjing Leads Biolabs Co., Ltd. listed on the Hong Kong Stock Exchange on July 25, 2025, under stock code 09887, raising approximately $189 million through its initial public offering.

The clinical-stage biotechnology company priced its IPO at HK$35 per share, offering 36.86 million shares excluding the green shoe option. The offering included 16.03 million shares in the Hong Kong public tranche and 20.84 million shares in the international placement. Morgan Stanley and CITIC Securities served as joint sponsors.

According to the company, proceeds will be allocated with approximately 65% for clinical trials and regulatory affairs, 15% for advancing preclinical assets and expanding pipelines, 10% for manufacturing capacity upgrades, and 10% for working capital and general corporate purposes.

Founded in 2012, Leads Biolabs develops therapies for oncology, autoimmune and other diseases. The company has 14 drug candidates in its pipeline, including six clinical-stage candidates.

The company operates through three main areas: immuno-oncology 2.0, T-cell engagers, and antibody-drug conjugates. Its oncology pipeline includes 12 investigational products comprising three monoclonal antibodies, five bispecific antibodies, three ADCs and one bispecific fusion protein.

Leads Biolabs presented data at the 2025 ASCO Annual Meeting for its lead candidate LBL-024, a PD-L1/4-1BB bispecific antibody. In a Phase Ib/II trial for advanced extra-pulmonary neuroendocrine carcinoma, the treatment showed a 75% objective response rate and 92.3% disease control rate among 52 evaluable patients.

China’s National Medical Products Administration approved a pivotal registrational trial for LBL-024 in EP-NEC on April 30, 2024. The candidate has received Breakthrough Therapy Designation from China’s NMPA and Orphan Drug Designation from the U.S. FDA.

The information is based on a company press release.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.